83 related articles for article (PubMed ID: 3890456)
1. Diminished sensitivity of platelet aggregation to prostaglandin D2 in patients with myeloproliferative disorders and in patients with acute leukemia.
Wong P; Fujioka S; Yoshida S
Nihon Ketsueki Gakkai Zasshi; 1985 Feb; 48(1):147-54. PubMed ID: 3890456
[No Abstract] [Full Text] [Related]
2. Platelet abnormality with no response to PGD2 in a patient with metastatic pancreas carcinoma and myeloproliferative disorder.
Kariya T; Suzuki H; Saito H; Higashihara M; Yamanaka M
Nihon Ketsueki Gakkai Zasshi; 1987 Feb; 50(1):168-74. PubMed ID: 3473883
[No Abstract] [Full Text] [Related]
3. Characterization of the platelet prostaglandin D2 receptor. Loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders.
Cooper B; Ahern D
J Clin Invest; 1979 Aug; 64(2):586-90. PubMed ID: 222813
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandins E1 and E2, but neither prostacyclin nor prostaglandin D2 have anti-aggregating activity in chicken blood.
Bult H; Wechsung E; Houvenaghel A; Herman AG
Arch Int Pharmacodyn Ther; 1981 Feb; 249(2):306-8. PubMed ID: 7013724
[No Abstract] [Full Text] [Related]
5. Evaluation of prostaglandin D2 (PGD2) as an anticoagulative agent for haemodialysis in comparison with prostaglandin E1 (PGE1).
Nakagawa S; Matsui N; Akiba T; Shinoda T; Fukudome Y; Ozawa K; Baba M; Nakanishi T; Takeuchi J
Proc Eur Dial Transplant Assoc; 1981; 18():117-21. PubMed ID: 7036145
[TBL] [Abstract][Full Text] [Related]
6. Anti-aggregatory prostanoids. Part I.
Korbut R; Gryglewski RJ
Acta Physiol Pol; 1985; 36(5-6):293-302. PubMed ID: 3915631
[TBL] [Abstract][Full Text] [Related]
7. Specificity between the anti-aggregatory actions of prostacyclin, prostaglandin E1 and D2 on platelets.
Whittle BJ; Hamid S; Lidbury P; Rosam AC
Adv Exp Med Biol; 1985; 192():109-25. PubMed ID: 2871707
[No Abstract] [Full Text] [Related]
8. Evaluation of prostaglandin and prostacyclin antagonism at platelet receptors by aggregometry.
Eggerman TL; Harker LA; Andersen NH; Wilson CH
Adv Prostaglandin Thromboxane Res; 1980; 6():389-93. PubMed ID: 6247888
[No Abstract] [Full Text] [Related]
9. Receptors and receptor mechanisms of endogenous platelet stimulatory and inhibitory mediators.
MacIntyre DE; Bushfield M; MacMillan LJ; Moffat KJ; Murdoch FA; Thomson A; Rossi AG; McNicol A
Agents Actions Suppl; 1986; 20():45-62. PubMed ID: 3028106
[No Abstract] [Full Text] [Related]
10. Platelet prostaglandin D2 dehydrogenase in patients with myeloproliferative disorders.
Sugiyama T; Okuma M; Uchino H
Prostaglandins Leukot Med; 1986 Feb; 21(2):207-20. PubMed ID: 3457389
[TBL] [Abstract][Full Text] [Related]
11. Effect of prostaglandin I2 and analogs on platelet aggregation and smooth muscle contraction.
Crane BH; Maish TL; Maddox YT; Corey EJ; Székely I; Ramwell PW
J Pharmacol Exp Ther; 1978 Jul; 206(1):132-8. PubMed ID: 351171
[No Abstract] [Full Text] [Related]
12. The antagonism of prostaglandins I2, E1 and D2 by prostaglandin E2 in human platelets.
Bonne C; Martin B; Watada M; Regnault F
Thromb Res; 1981 Jan 1-15; 21(1-2):13-22. PubMed ID: 6262942
[No Abstract] [Full Text] [Related]
13. The effect of prostacyclin (PGT2) on platelet behaviour. Thrombus formation in vivo and bleeding time.
Ubatuba FB; Moncada S; Vane JR
Thromb Haemost; 1979 Apr; 41(2):425-35. PubMed ID: 382434
[TBL] [Abstract][Full Text] [Related]
14. 9-deoxy-delta 9-prostaglandin D2, a prostaglandin D2 derivative with potent antineoplastic and weak smooth muscle-contracting activities.
Fukushima M; Kato T; Ota K; Arai Y; Narumiya S; Hayaishi O
Biochem Biophys Res Commun; 1982 Dec; 109(3):626-33. PubMed ID: 6961920
[No Abstract] [Full Text] [Related]
15. Prostaglandin releasing polymers - stability and efficacy.
McRea JC; Ebert CD; Kim SW
Trans Am Soc Artif Intern Organs; 1981; 27():511-6. PubMed ID: 7036503
[TBL] [Abstract][Full Text] [Related]
16. [The platelet defect in myeloproliferative disorder (author's transl)].
Delobel J
Nouv Rev Fr Hematol (1978); 1976; 16(3):443-6. PubMed ID: 1012918
[TBL] [Abstract][Full Text] [Related]
17. Characterization of controlled release of prostaglandin from polymer matrices for thrombus prevention.
McRea JC; Kim SW
Trans Am Soc Artif Intern Organs; 1978; 24():746-52. PubMed ID: 362677
[No Abstract] [Full Text] [Related]
18. Effects of indomethacin and prostaglandins E2, I2, and D2 on the fetal circulation.
Sideris EB; Yokochi K; Van Helder T; Coceani F; Olley PM
Adv Prostaglandin Thromboxane Leukot Res; 1983; 12():477-82. PubMed ID: 6221634
[No Abstract] [Full Text] [Related]
19. The effect of 5-(2-chlorobenzyl)-5,6,7,7a-tetrahydro 4H-thieno (3.2-C)-pyridine-2-one hydrochloride (PCR 3787), a metabolite of ticlopidine, on the aggregation of human platelets in vitro and on the aggregation inhibiting action of PGI2 and PGD2.
Vincent JE; Zijlstra FJ; de Wit CM; Bonta IL
Prostaglandins Leukot Med; 1984 Dec; 16(3):279-83. PubMed ID: 6396655
[TBL] [Abstract][Full Text] [Related]
20. Refractoriness of platelets to prostaglandins after infusion in rabbits.
Bertelé V; Stemerman M; Schafer A; Adelman B; Smith M; Fuhro R; Salzman E
J Lab Clin Med; 1985 Nov; 106(5):551-61. PubMed ID: 2997353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
